Potential Cooperation Between Russia and India Regarding the Production of Pharmaceuticals Beneficial for Both Parties
Frost & Sullivan’s analysts comment on India’s plan to invest in the Russian pharmaceutical industry
India is ready to invest in the Russian pharmaceutical industry, including India-Russia joint ventures, as India's Commerce and Industry Minister, Anand Sharma, said during his visit to Russia last week. Among other resources and technologies, India is very keen in developing biotechnologies, nanotechnologies and other sciences such as genomics and bioinformatics, thereby entering the Russian healthcare industry.
“India is one of the largest manufacturers of generics in the market. At present, Russia is making a list of all the prescribed medicines it needs and Indian and Russian governments are working on a protocol which will stipulate production, manufacturing capabilities and safety standards. Top drug therapeutic areas in Russia include CNS, anti-diabetics, cold and cough medications,” says Frost & Sullivan Research Analyst, Ms. Swetha Shantikumar.
“In the late 90s and early 2000s, there was a very strong pharma import activity from India to Russia. At that time, Russia's main objective was to clear its debt through the Centralized Purchase System (CPS) by buying out useful commodities from India, in which pharmaceuticals also formed a major bulk,” she continuous.
“A potential cooperation between Russia and India seems very beneficial for both parties. Indian manufacturers can benefit from the fact that Russia is in the midst of pharmaceutical sector reform, known as Pharma 2020, which aims at strengthening the domestic production capacities,” adds Frost & Sullivan Consulting Analyst, Miss Dominika Grzywinska. “Therefore, those pharmaceutical companies which decide to open their production facilities in the country can count on certain sets of privileges, such as lower taxes or easier access to reimbursement lists. The entry of Indian pharmaceutical companies will help Russia fulfill the assumptions of the Pharma 2020 reform, i.e. making pharmaceuticals more accessible to citizens, strengthening domestic production and containing the ever-growing expenditure on drugs.”
Most read news
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
New mechanism of pancreatic cancer discovered
Unconventional natural gas wells associated with migraine, fatigue
Pieris Initiates Phase I Clinical Trial for Lead Anticalin Compound - Anti-VEGF PRS-050 is first Anticalin tested in humans
New combination therapy looks promising against ulcer bacteria
European Medicines Agency advises on compassionate use of daclatasvir - Opinion concerns use in combination with sofosbuvir in patients with chronic hepatitis C in urgent need of therapy to prevent progression of liver disease
Novartis completes shipment of US supply of Fluvirin seasonal influenza vaccine
A Change of Culture for Healthcare
Medicyte GmbH Benefits From Multi-Million Euro EU Grant VascuBone
Pneumonoultramicroscopicsilicovolcanoconiosis

Biofilms - an invisible threat to food safety - Hotspots for biofilms

Snake venom treatment investigated as antibiotic alternative for eye infections
